ClinicalTrials.Veeva

Menu

Population Pharmacokinetics and Clinical Individual Dosage Regimen of Propofoll Injection

Z

Zhongyuan Xu

Status

Unknown

Conditions

General Anesthesia

Treatments

Drug: Propofol

Study type

Interventional

Funder types

Other

Identifiers

NCT03422315
C1033453

Details and patient eligibility

About

Propofol is a widely used sedative anesthetic, but there are large individual differences, which making different patients with different sensitivity to propofol. The aim of this study was to analyze the effects of age, height, body weight, Drinking, metabolic enzymes CYP2B6 and UGT1A9 on Pharmacological effects and pharmacokinetics of propofol, and to provide a reasonable reference for clinical anesthesia patients and evidence for individual dosage regimens.

Full description

Propofol is a widely used sedative anesthetic, but there are large individual differences, which making different patients with different sensitivity to propofol. In recent years, the concept of individualized administration came into being.Individual administration refers to according to the condition of patients,the drug's safety and efficacy, and pharmacokinetics, pharmacodynamics and clinical response ,then gives different dosing regimens for individual patients and promotes the development of rational drug use. Different people have differences metabolism of propofol, reported in the literature, genetic polymorphism, demographic characteristics, combined with drug and other variability factors, all of them will affect the pharmacokinetics and pharmacodynamics of propofol.The aim of this study was to analyze the effects of age, height, body weight, Drinking, metabolic enzymes CYP2B6 and UGT1A9 on Pharmacological effects and pharmacokinetics of propofol, and to provide a reasonable reference for clinical anesthesia patients and evidence for individual dosage regimens.

Enrollment

60 estimated patients

Sex

All

Ages

18 to 60 years old

Volunteers

No Healthy Volunteers

Inclusion criteria

  • patients aged 18-60 years (including those aged 18 and 60) who underwent gastrointestinal endoscopy;
  • weight should not be less than (≥) 50kg, not more than (≤) 80kg. Body mass index (BMI) = body weight kg / [(height m) 2], in the normal range of 19 to 25;
  • American Society of Anesthesiologists (ASA) grading (Appendix I): I or II;
  • no heart, liver, lung, kidney, digestive tract, nervous system, mental disorders and other medical history, no blood and metabolic diseases and other medical history, no potential difficulties airway and special past history,
  • blood, urine, stool routine, liver and kidney function, blood lipids, ECG, chest X-ray and blood pressure normal, or abnormal but no clinical significance, the researchers believe that can be grouped.
  • agree and sign informed consent.

Exclusion criteria

  • important organs have primary disease;
  • persons with mental or physical disabilities;
  • those suffering from neurological or mental illness, a history of epilepsy;
  • patients with cardiovascular or respiratory insufficiency and hypovolemia;
  • obese or those with dyslipidemia;
  • hereditary acute porphyria;
  • infections, especially those with respiratory and central infections;
  • language exchange barriers;
  • suspected or indeed a history of alcohol, drug abuse; especially long-term use of non-steroidal anti-inflammatory drugs, opioids, tranquilizers;
  • allergies, if the history of drugs or food allergies; or known to propofol, soybeans, peanuts, coconut oil allergy;
  • smoking history (smoking ≥ 5 per day);
  • 2 weeks before the trial had used all kinds of Chinese and Western medicine;
  • the last 3 months of blood donors and test blood donors;
  • other circumstances that the researcher thinks can not be grouped (eg, frail, etc.).

Trial design

Primary purpose

Basic Science

Allocation

N/A

Interventional model

Single Group Assignment

Masking

None (Open label)

60 participants in 1 patient group

External control
Experimental group
Description:
propofol;injection;2mg/kg;single-dose
Treatment:
Drug: Propofol

Trial contacts and locations

1

Loading...

Central trial contact

wanwen cao, master; zhongyuan xu, Ph.D.

Data sourced from clinicaltrials.gov

Clinical trials

Find clinical trialsTrials by location
© Copyright 2026 Veeva Systems